Premature Rupture of Membranes (PROM) Testing Market - By Product Type (Ultrasound, Nitrazine Test, Ferning Test, Pooling Test), By End-use (Hospitals, Diagnostic Laboratories) – Global Forecast to 2032

Premature Rupture of Membranes Testing Market Size

Premature Rupture of Membranes (PROM) Testing Market size was valued at over USD 3 billion in 2022 and is estimated to grow at a 5.7% CAGR between 2023 to 2032. Premature rupture of membranes (PROM) diagnostic techniques and instruments are used to find and evaluate foetal membrane rupture prior to the beginning of labour. The aim of PROM testing is to verify the membrane rupture, diagnose the severity of the disease, and determine the most appropriate line of treatment for the patient.
 

Increasing awareness about PROM-related complications, advancements in diagnostic technologies are few aspects driving the growth of the premature rupture of membranes testing industry during projected timeframe.
 

Moreover, continuous growth in the prevalence rate of preterm births is further augmenting the growth of the premature rupture of membranes (PROM) testing market. For instance, according to the World Health Organization (WHO), more than 15 million new-borns are born preterm. Also, around 1 million deaths are associated with preterm complications each year across the world. As preterm birth is a risk factor for PROM, the increasing prevalence of preterm births directly contributes to the higher demand for PROM testing and the development of innovative testing technologies, including advanced diagnostic tools and improved methodologies, to meet the growing demand.
 

COVID-19 Impact

The pandemic has disrupted healthcare systems globally, causing changes in healthcare priorities, resource allocation, and patient access to care. The COVID-19 pandemic had adversely affected on the premature rupture of membranes (PROM) testing market.  Many healthcare facilities have been overwhelmed by the surge in COVID-19 cases, leading to a diversion of resources and personnel to pandemic response efforts. Non-essential medical procedures, including PROM testing had delayed or postponed resulted in reduced testing rates and access to diagnostic services. As a result, demand for premature rupture of membranes (PROM) testing had declined significantly. Fear of infection and restrictions on movement have resulted in reduced patient visits to healthcare facilities, including for routine prenatal care. This reduction in patient visits have led to underdiagnosis or delayed diagnosis of PROM, affecting the demand for testing. As a result, the COVID-19 restricted the expansion of the PROM testing market.
 

Premature Rupture of Membranes Testing Market Trends

The rising development of new and improved diagnostic tests will accelerate the PROM testing market. Advancements in diagnostic technologies and the introduction of novel testing methods have the potential to enhance the accuracy, efficiency, and accessibility of PROM testing, thereby improving patient outcomes and driving market growth. The development of enhanced PROM testing for quick and reliable PROM identification has been continuously occurring. This includes the advancement of biomarkers such as insulin-like growth factor-binding protein-1 (IGFBP-1) and placental alpha-microglobulin-1 (PAMG-1). Moreover, a surge in the prevalence of diabetes and cardiovascular diseases doubles a woman's future risk of premature rupture of membranes (PROM). This has resulted in increasing demand for PROM testing and is anticipated to drive market expansion in the future years.
 

Premature Rupture of Membranes (PROM) Testing Market Analysis

The premature rupture of membranes testing market by product type is segmented into nitrazine test, ferning test, pooling test, ultrasound, and others. The nitrazine test segment is predicted to witness CAGR of 5.7% during the forecast period. Continuous technological advancements and integration of digital solutions in nitrazine test to enhance accuracy, ease of use, and interpretation will foster segmental growth. Also, integration of digital solutions to enhance result interpretation and documentation by providing objective colour analysis, automate result interpretation, and enable seamless data integration with electronic medical records (EMRs). Moreover, several manufacturers are developing innovative Nitrazine test strips and swabs with improved sensitivity and specificity to gain more reliable and precise results.

The premature rupture of membranes testing market by end-use is categorized into hospitals, diagnostic laboratories and others. Diagnostic laboratories segment held largest revenue size accounting for over USD 2 billion in 2022 and is forecasted to dominate the regional market throughout the analysis period. The high segment growth is attributable to early diagnosis of PROM to avoid devastating and life-threatening maternal hazards. The growing recognition of the importance of early and accurate diagnosis of PROM leading to an increased demand for PROM testing.
 

Growing demand for diagnostic laboratories owing to upsurge in the number of samples for analysis, necessitating the need to scale up their testing capacity and optimize workflows to meet the growing demand. Moreover, the consideration of presently accessible widely recognized standard guidelines of PROM testing and the availability of skilled professionals among the settings is one of the major driving factors for the diagnostic laboratories segment in the PROM testing market.

U.S. premature rupture of membranes testing market accounted for USD 1 billion in 2022 and is anticipated to witness substantial industry growth over the projected period. Rising prevalence rate of preterm births across the nation is driving the PROM Testing market. For instance, Centers For Disease Control and Prevention, in United States, around 1 out of 10 infants associated with preterm birth in the year 2022.  Growing emphasis on improving neonatal outcomes, healthcare providers are increasingly recognizing the importance of PROM testing accelerating the demand for diagnostic services. Growing awareness about the importance of early detection and management of PROM is driving increased screening efforts. Public health initiatives, educational campaigns, and awareness programs conducted by healthcare organizations and government agencies creating a greater emphasis on PROM testing.
 

Premature Rupture of Membranes (PROM) Testing Market Share

Some of the notable key industry players operating in the premature rupture of membranes testing market include

• Abbott Laboratories
• QIAGEN
• Hologic Inc.
• Medix Biochemica
• Biosynex
• Clinical Innovations LLC
• Sera Prognostics Inc.
• The Cooper Companies Inc.
• NX Prenatal Inc.
• IQ Products

These market participants are undertaking numerous growth strategies such as partnerships, collaborations, acquisitions & mergers, and new product development & launches to strengthen product offerings as well as gain a competitive edge over others.
 

Premature Rupture of Membranes (PROM) Testing Industry News:

• In January 2023, QIAGEN partnered with Helix for development and commercialization of companion diagnostics for several hereditary diseases. Through this partnership, Helix Laboratory Platform will create companion diagnoses in the United States while QIAGEN will utilize the QIASeq Human Exome Kits in the rest of the globe for the diagnosis of a variety diseases. This has helped the company to expand its operational capabilities in significant market.
   
• In June 2022, Medix Biochemica acquired Bioresource Technology Inc. a prominent player in critical raw materials for IVD quality control products production. This acquisition broadened the company’s offerings in the in-vitro diagnostics business.
   

Premature rupture of membranes (PROM) testing market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032 for the following segments:

Click here to Buy Section of this Report

By Product Type

• Nitrazine test
• Ferning test
• Pooling test
• Ultrasound
• Others

By End-use

• Hospitals
• Diagnostic laboratories
• Others

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Switzerland
  • The Netherlands
  • Poland
  • Sweden
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Indonesia
  • Thailand
  • Vietnam
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Chile
  • Peru
• Middle East & Africa
  • Saudi Arabia
  • South Africa
  • UAE